Tema Obesity & Cardiometabolic ETF

HRTS
ETF Ticker

+2.63%

+12.67%

NASDAQ

Equity

Global

Thematic

The Tema Obesity & Cardiometabolic ETF, HRTS_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NASDAQ and has assets under management of $56.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Nov 20, 2023. It has a net expense ratio of 75bps. (All data in USD as of Oct 9, 2026 unless stated.)

The investment strategy underpinning the actively managed Tema Obesity & Cardiometabolic ETF targets companies advancing prevention, diagnosis, treatment, and long-term management of obesity and cardiometabolic disease across biopharma, medical devices, diagnostics, nutrition, and enabling supply chains. The universe is global but typically focused on U.S.-listed liquidity. Security selection combines fundamental research, pipeline and commercial-stage risk assessment, regulatory and reimbursement visibility, and revenue-exposure mapping to obesity and related metabolic pathways. Portfolio construction balances conviction with diversification using issuer and industry caps, liquidity and capacity screens, and active-risk bands to manage binary event concentration. Rebalancing is event-driven around clinical catalysts, label updates, competitive read-throughs, and valuation discipline; positions are trimmed or exited on thesis drift, deteriorating risk-reward, balance-sheet stress, or liquidity shortfalls. Cash levels and position sizes adjust to reflect upcoming catalysts and modelled downside in adverse outcomes.

ETF Details

Key Facts

Issuer:
Tema
AUM:
$56.0m (as of Aug 31, 2026)
Net Expense Ratio:
75 bps
Inception Date:
Nov 20, 2023
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
HRTS
Exchange:
NASDAQ
ISIN:
US87975E8839
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
16.15%
3 Year Volatility:
N/A
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
1.45% (verify with issuer)
1 Month Performance:
-0.85%
3 Month Performance:
-2.41%
6 Month Performance:
5.82%
1 Year Performance:
12.67%
3 Year Performance:
N/A
5 Year Performance:
N/A
Investment Proposition

Tema Obesity & Cardiometabolic ETF (HRTS) offers targeted exposure to companies addressing obesity, diabetes, and related cardiometabolic conditions through pharmaceuticals, devices, digital tools, nutrition, and care delivery. The strategy pursues growth by focusing on platforms with scalable mechanisms of action, complementary diagnostics, and integrated care models, while recognizing the competitive intensity and evolving standards of care in metabolic medicine. Portfolio traits may lean toward quality growth with catalysts tied to clinical data, label expansions, manufacturing scale-up, and access decisions, creating return paths that can diverge from broad healthcare. As a portfolio role, HRTS fits as a thematic satellite for innovation allocators or as a completion sleeve to sharpen exposure to metabolic health within diversified healthcare. It can be supported when clinical outcomes strengthen, manufacturing capacity expands, and payer coverage stabilizes, and challenged during policy scrutiny, safety debates, or shifting therapeutic preferences. A fund-specific risk to monitor is concentration in leading therapeutic classes, where pricing, competition, or supply dynamics for a few franchises can meaningfully influence outcomes.

ETF Analytics

Fund Discovery

4 Suggestions